XR-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the effective management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The extended-release formulation ensures sustained therapeutic plasma concentrations, improving patient compliance by reducing dosing frequency. XR-DSR Capsule is indicated for patients requiring both acid suppression and prokinetic effects to alleviate symptoms of GERD, erosive esophagitis, and functional dyspepsia. It should be used under medical supervision, with consideration of contraindications such as hypersensitivity to components, and caution in patients with cardiac arrhythmias or hepatic impairment. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Drug interactions should be carefully evaluated, particularly with medications metabolized via CYP3A4. Overall, XR-DSR Capsule offers a synergistic approach to managing complex upper GI disorders by combining acid suppression and enhanced gastric motility.